Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cobalt Biomedicine
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
Cobalt Biomedicine was focused on engineering fusogens to deliver diverse biotherapeutic payloads, demonstrating preclinical proof of concept for delivery to various cell types. The entity merged into Sana Biotechnology in early 2019 and ceased to exist as an independent entity; Sana now continues to develop these technologies. No clinical-stage programs originating from Cobalt were reported as of the merger.
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesImmunology
- Modalities
- Gene therapyCell therapyRNA therapyProteinmRNA-based drugsLipid nanoparticle delivery therapyExosome-based therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Cobalt Biomedicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cobalt Biomedicine.